head of Lilly Oncology. The agreement isn't Lilly's first attempt to make a mark in the PI3K inhibitor class, having previously been working on LOXO-783, a drug it acquired as part of its $8 ...

Jake Van Naarden, executive vice president and president, Lilly Oncology, will take part in a fireside chat at 1:50 p.m., Eastern time. A live audio webcast will be available on the "Webcasts ...

It is tailored to patients being treated with Lilly's oncology drugs – which include blockbuster CDK 4/ 6 inhibitor Verzenio (abemaciclib) for hormone receptor-positive, HER2-negative breast ...

The molecular glue wave that first began years ago is still swelling, with Eli Lilly earmarking approximately $1.25 billion ...

The molecular glue space has attracted several Big Pharma players over the past few years, including Novo Nordisk, Pfizer and ...

We recently published a list of the 11 Best Pharma Stocks to Buy According to Hedge Funds. In this article, we are going to ...

Joining us from the Company is Jake Van Naarden, who is President of Lilly Oncology. So, thank you so much, Jake, for being with us. Yes. So, I think, in the late phase portfolio on the R&D side ...

Magnet Biomedicine has entered a partnership and licence agreement with Eli Lilly to discover, develop and commercialise ...

Eli Lilly and Co. is in negotiations with several states and plans to announce the locations of four new manufacturing plants later this year.

Advertisement Eli Lilly chairman and Chief Executive Officer ... to produce medicines that support cardio-metabolic health, oncology, immunology and neuroscience treatments.